Cargando…

Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma

Background: Sanguisorba Officinalis L. (SO) is a well-known traditional Chinese medicine (TCM), commonly applied to treat complex diseases, such as anticancer, antibacterial, antiviral, anti-inflammatory, anti-oxidant and hemostatic effects. Especially, it has been reported to exert anti-tumor effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Nan, Li, Hong, Sun, Yueshan, Zeng, Jing, Yang, Fei, Kantawong, Fahsai, Wu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969657/
https://www.ncbi.nlm.nih.gov/pubmed/33746755
http://dx.doi.org/10.3389/fphar.2021.618522
_version_ 1783666271172165632
author Jiang, Nan
Li, Hong
Sun, Yueshan
Zeng, Jing
Yang, Fei
Kantawong, Fahsai
Wu, Jianming
author_facet Jiang, Nan
Li, Hong
Sun, Yueshan
Zeng, Jing
Yang, Fei
Kantawong, Fahsai
Wu, Jianming
author_sort Jiang, Nan
collection PubMed
description Background: Sanguisorba Officinalis L. (SO) is a well-known traditional Chinese medicine (TCM), commonly applied to treat complex diseases, such as anticancer, antibacterial, antiviral, anti-inflammatory, anti-oxidant and hemostatic effects. Especially, it has been reported to exert anti-tumor effect in various human cancers. However, its effect and pharmacological mechanism on hepatocellular carcinoma (HCC) remains unclear. Methods: In this study, network pharmacology approach was applied to characterize the underlying mechanism of SO on HCC. Active compounds and potential targets of SO, as well as related genes of HCC were obtained from the public databases, the potential targets and signaling pathways were determined by protein-protein interaction (PPI), gene ontology (GO) and pathway enrichment analyses. And the compound-target and target-pathway networks were constructed. Subsequently, in vitro experiments were also performed to further verify the anticancer effects of SO on HCC. Results: By using the comprehensive network pharmacology analysis, 41 ingredients in SO were collected from the corresponding databases, 12 active ingredients screened according to their oral bioavailability and drug-likeness index, and 258 potential targets related to HCC were predicted. Through enrichment analysis, SO was found to show its excellent therapeutic effects on HCC through several pathways, mainly related to proliferation and survival via the EGFR, PI3K/AKT, NFκB and MAPK signaling pathways. Additionally, in vitro, SO was found to inhibit cell proliferation, induce apoptosis and down-regulate cell migration and invasion in various HCC cells. Moreover, western blot analysis showed that SO treatment down-regulated the expression of p-EGFR, p-PI3K, p-AKT, p-NFκB and p-MAPK proteins in HepG2 cells. These results validated that SO exerted its therapeutic effects on HCC mainly by the regulation of cell proliferation and survival via the EGFR/MAPK and EGFR/PI3K/AKT/NFκB signaling pathways. Conclusion: Taken together, this study, revealed the anti-HCC effects of SO and its potential underlying therapeutic mechanisms in a multi-target and multi-pathway manner.
format Online
Article
Text
id pubmed-7969657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79696572021-03-19 Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma Jiang, Nan Li, Hong Sun, Yueshan Zeng, Jing Yang, Fei Kantawong, Fahsai Wu, Jianming Front Pharmacol Pharmacology Background: Sanguisorba Officinalis L. (SO) is a well-known traditional Chinese medicine (TCM), commonly applied to treat complex diseases, such as anticancer, antibacterial, antiviral, anti-inflammatory, anti-oxidant and hemostatic effects. Especially, it has been reported to exert anti-tumor effect in various human cancers. However, its effect and pharmacological mechanism on hepatocellular carcinoma (HCC) remains unclear. Methods: In this study, network pharmacology approach was applied to characterize the underlying mechanism of SO on HCC. Active compounds and potential targets of SO, as well as related genes of HCC were obtained from the public databases, the potential targets and signaling pathways were determined by protein-protein interaction (PPI), gene ontology (GO) and pathway enrichment analyses. And the compound-target and target-pathway networks were constructed. Subsequently, in vitro experiments were also performed to further verify the anticancer effects of SO on HCC. Results: By using the comprehensive network pharmacology analysis, 41 ingredients in SO were collected from the corresponding databases, 12 active ingredients screened according to their oral bioavailability and drug-likeness index, and 258 potential targets related to HCC were predicted. Through enrichment analysis, SO was found to show its excellent therapeutic effects on HCC through several pathways, mainly related to proliferation and survival via the EGFR, PI3K/AKT, NFκB and MAPK signaling pathways. Additionally, in vitro, SO was found to inhibit cell proliferation, induce apoptosis and down-regulate cell migration and invasion in various HCC cells. Moreover, western blot analysis showed that SO treatment down-regulated the expression of p-EGFR, p-PI3K, p-AKT, p-NFκB and p-MAPK proteins in HepG2 cells. These results validated that SO exerted its therapeutic effects on HCC mainly by the regulation of cell proliferation and survival via the EGFR/MAPK and EGFR/PI3K/AKT/NFκB signaling pathways. Conclusion: Taken together, this study, revealed the anti-HCC effects of SO and its potential underlying therapeutic mechanisms in a multi-target and multi-pathway manner. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC7969657/ /pubmed/33746755 http://dx.doi.org/10.3389/fphar.2021.618522 Text en Copyright © 2021 Jiang, Li, Sun, Zeng, Yang, Kantawong and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jiang, Nan
Li, Hong
Sun, Yueshan
Zeng, Jing
Yang, Fei
Kantawong, Fahsai
Wu, Jianming
Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title_full Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title_fullStr Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title_full_unstemmed Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title_short Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma
title_sort network pharmacology and pharmacological evaluation reveals the mechanism of the sanguisorba officinalis in suppressing hepatocellular carcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969657/
https://www.ncbi.nlm.nih.gov/pubmed/33746755
http://dx.doi.org/10.3389/fphar.2021.618522
work_keys_str_mv AT jiangnan networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT lihong networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT sunyueshan networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT zengjing networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT yangfei networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT kantawongfahsai networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma
AT wujianming networkpharmacologyandpharmacologicalevaluationrevealsthemechanismofthesanguisorbaofficinalisinsuppressinghepatocellularcarcinoma